Results 41 to 50 of about 4,040 (201)

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection. [PDF]

J Pediatr Pharmacol Ther
Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract
Sano U, Meyers R, Hasan U, Smoke S.
europepmc   +2 more sources

2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates

Open Forum Infectious Diseases, 2023
Abstract Background Burkholderia species can cause chronic and often severe respiratory tract infections in cystic fibrosis (CF) patients. The treatment of infections Burkholderia isolates is complicated by low cell permeability to most antimicrobial agents, presence of beta-lactamases and expression ...
Castanheira, Mariana, Shortridge, Dee, Fedler, Kelley, Carvalhaes, Cecilia G   +3 more
openaire   +1 more source

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

Antibiotics, 2021
The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients.
Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong, Taotao Wang   +7 more
doaj   +1 more source

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

Frontiers in Microbiology, 2021
QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam).
Olga Lomovskaya, Ruslan Tsivkovski, Dongxu Sun, Raja Reddy, Maxim Totrov, Scott Hecker, David Griffith, Jeffery Loutit, Michael Dudley   +8 more
doaj   +1 more source

Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment. [PDF]

, 2017
PURPOSE OF REVIEW: This review summarizes the main challenges of antimicrobial resistance (AMR) in the neonatal population with a special focus on multidrug-resistant (MDR) Gram-negative pathogens.
Bielicki, J, Folgori, L, Heath, PT, Sharland, M   +3 more
core   +1 more source

Evaluation of a hybrid antimicrobial restriction process at a large academic medical center [PDF]

, 2021
We conducted a retrospective review of a hybrid antimicrobial restriction process demonstrating adherence to appropriate use criteria in 72% of provisional-only orders, in 100% of provisional orders followed by ID orders, and in 97% of ID-initiated ...
Durkin, Michael J, Hsueh, Kevin, Krekel, Tamara, Neuner, Elizabeth A, Nguyen, Linh H, Ritchie, David J, Smith, Jesse D, Waggoner, Jerrica   +7 more
core   +2 more sources

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations

Journal of Global Antimicrobial Resistance, 2023
: Objectives: Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (
A. Oliva, D. Al Ismail, G. Arcari, MC. Miele, E. Casali, F. Sacco, L. Volpicelli, M. De Angelis, M.T. Mascellino, F. Cancelli, G. Raponi, A. Carattoli, M Venditti   +12 more
doaj   +1 more source

Nieuwe antibiotica werkzaam tegen multiresistente gramnegatieve bacteriën [PDF]

, 2021
Infecties door gramnegatieve bacteriën zijn lastig te behandelen wanneer deze bacteriën resistent zijn voor β-lactamantibiotica. De afgelopen 5 jaar zijn door het Europees Geneesmiddelenbureau en het Amerikaanse Food and Drug Administration nieuwe ...
Bax, Hannelore, Dix, Laura, van Westreenen, Mireille, Verkaik, Nelianne, Yusuf, Erlangga   +4 more
core  

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam [PDF]

, 2022
We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system ...
Avison, Matthew B, Dulyayangkul, Punyawee, Satapoomin, Aim   +2 more
core   +2 more sources

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

Drugs, 2018
The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials. Intravenous meropenem/vaborbactam (Vabomere™) is the first carbapenem/β-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis ...
openaire   +2 more sources